IMMU-43. ZIKA VIRUS TO TREAT GLIOMA: TURNING COLD TUMORS HOT

作者
Luciano Mazzoccoli,Sharmila Nair,Arijita Jash,Jennifer Govero,Tong Hu,Sujan Shresta,Pei‐Yong Shi,Jeremy N. Rich,Michael Diamond,Milan G. Chheda
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:22 (Supplement_2): ii114-ii114
标识
DOI:10.1093/neuonc/noaa215.473
摘要

Abstract GBM is a hallmark example of an immunotherapy-resistant tumor. Previously, we discovered that Zika virus (ZIKV) has a natural honing capacity to specifically kill GBM stem cells (GSCs). Using two syngeneic glioma models, GL261 and CT2A, we found that in vivo intratumoral ZIKV treatment reduces tumor size and extends median survival far beyond that expected for its anti-GSC effects; additionally, approximately 50% of mice were long-term survivors. We now report that ZIKV treatment is associated with an increase in tumor-specific CD8+ T cells and activated myeloid cells expressing MHC-II and NOS2. Treatment with CD8-depleting antibody abrogates the survival advantage conferred by ZIKV, demonstrating that CD8+ T cells are required for ZIKV efficacy. Remarkably, ZIKV treatment also confers protection against tumor re-challenge 1.5 years after the original treatment, and this too is dependent on CD8+ T cells. Lastly, in a bilateral tumor implantation model, intratumoral ZIKV treatment of one tumor increases overall survival, suggesting ZIKV is efficacious because it generates a global anti-tumor response. Building on the observation that ZIKV treatment increases CD8+ T cells in the tumor bed, we combined ZIKV with α-PD1 immunotherapy. We found survival was dramatically increased compared to either treatment alone. Finally, to improve safety of potential ZIKV treatment for patients, we generated an immune-sensitized virus. This strain remains efficacious as a single agent and in combination with immunotherapy in vivo. Overall, our results suggest ZIKV treatment addresses two key problems in our current treatment of GBM: it specifically targets highly resistant GSC and initiates a potent anti-tumor immune response against the remaining tumor. Our work reveals the mechanistic basis of ZIKV efficacy and demonstrates the potential for ZIKV as a therapy for GBM.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
深情安青的应助被三分之二采纳,获得10
1秒前
yunlong完成签到 ,获得积分10
2秒前
2秒前
2秒前
西陆发布了新的文献求助10
3秒前
WilliamTT发布了新的文献求助10
3秒前
东方天奇完成签到 ,获得积分10
3秒前
4秒前
syvshc的应助被RuYi采纳,获得10
4秒前
5秒前
慕青的应助被阿耒采纳,获得10
5秒前
5秒前
SchoLar完成签到 ,获得积分10
5秒前
慕青的应助被脑子大聪明采纳,获得10
5秒前
6秒前
6秒前
6秒前
7秒前
TCA关注了科研通微信公众号
7秒前
7秒前
科研通AI65的应助被小白采纳,获得10
7秒前
寻找布冯发布了新的文献求助10
8秒前
1111111完成签到,获得积分10
8秒前
8秒前
8秒前
lele发布了新的文献求助10
8秒前
fantasy的应助被和道一文字采纳,获得10
9秒前
动听千山发布了新的文献求助10
9秒前
玉米侠发布了新的文献求助10
10秒前
星燃发布了新的文献求助10
10秒前
Cuzz关注了科研通微信公众号
11秒前
11秒前
拼搏可冥发布了新的文献求助10
12秒前
Artsy发布了新的文献求助10
13秒前
Jasper的应助被三分之二采纳,获得10
13秒前
13秒前
cc发布了新的文献求助20
13秒前
zys完成签到,获得积分10
13秒前
13秒前
YEYE发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034